Skip to main content

Table 4 Lipid profile of adult patients on lipid-lowering treatment

From: Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry

Parameter Adults
Statin ± Ezetimibe
(n = 891)
Statin ± Ezetimibe + PCSK9i
(n = 59)
Pre-treatment Post-treatment Pre-treatment Post-treatment
Total cholesterol, mg/dL
(mmol/L)
326 ± 79
(8.4 ± 2.0)
225 ± 63††
(5.8 ± 1.6)††
392 ± 123
(10.1 ± 3.2)
215 ± 109††
(5.6 ± 2.8)
Triglycerides, mg/dL
(mmol/L)
128 (94–179)
[1.4 (1.4–2.0)]
110 (80–154)††
[1.2 (0.9–1.7)]††
140 (99–192)
[1.6 (1.1–2.2)]
108 (75–153)††
[1.2 (0.8–1.7)]††
HDL-C, mg/dL
(mmol/L)
51 ± 14
(1.3 ± 0.4)
51 ± 15
(1.3 ± 0.4)
51 ± 13
(1.3 ± 0.3)
50 ± 14
(1.3 ± 0.3)
non-HDL-C, mg/dL
(mmol/L)
275 ± 79
(7.1 ± 2.0)
174 ± 63††
(4.5 ± 1.6)††
342 ± 119
(8.8 ± 3.1)
164 ± 106††
(4.2 ± 2.7)††
LDL-CF, mg/dL
(mmol/L)
244 ± 68
(6.3 ± 1.8)
149 ± 59††
(3.9 ± 1.5)††
311 ± 118
(8.0 ± 3.1)
141 ± 103††
(3.6 ± 2.7)††
LDL-CM/H, mg/dL
(mmol/L)
244 ± 68
(6.3 ± 1.8)
150 ± 59††
(3.9 ± 1.5)††
311 ± 118
(8.0 ± 3.1)
141 ± 102††
(3.6 ± 2.6)††
aLDL-CLp(a)corM/H, mg/dL
(mmol/L)
243 ± 77
(6.3 ± 2.0)
118 ± 52†,§,††
(3.1–1.3)†,§,††
-b -b
aLp(a), mg/dL
(nmol/L)
25 (10–68)
[50.7 (18.0–144)]
26 (10–68)
[52.9 (18.0–144)]
-b -b
  1. Data are presented as mean ± standard deviation or median (interquartile range) for parametric and non-parametric variables, respectively
  2. HDL-C High-density lipoprotein cholesterol, LDL-CF Low-density lipoprotein cholesterol as calculated by the Friedewald formula, LDL-CM/H Low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, LDL-CLp(a)corM/H Corrected for Lp(a) levels low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, PCKS9i Proprotein convertase subtilisin/kexin type 9 inhibitor, Lp(a) was converted using the formula: Lp(a) nmol/L = 2.18 × Lp(a) mg/dL − 3.83
  3. P < 0.001 vs LDL-CF and LDL-CM/H, §P < 0.001 for the comparison of LDL-C change compared with the change of LDL-CF and LDL-CM/H,††P < 0.001 vs pre-treatment
  4. a: Data available for 342 patients
  5. b: Data for Lp(a) levels in adult patients treated with PCSK9i were available only for 5 patients and thus were not included in the analysis